Mar 05, 2026
BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid WithdrawalVIEW RELEASE
Feb 19, 2026
BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer’s DementiaVIEW RELEASE
Feb 12, 2026
BioXcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for IGALMI® in the At-Home SettingVIEW RELEASE
Stock Information
BioXcel Therapeutics, Inc.
Mar 05, 2026 03:28 PM
MARKET/SYMBOL
Nasdaq:
BTAI
PRICE
1.65
CHANGE
0 (0%)
